David Berry MD, PhD

David Berry joined Flagship Pioneering in 2005. Trained as an M.D./Ph.D., David brings a multifaceted perspective to ­his work in conceiving, creating, resourcing and launching groundbreaking companies at Flagship. David holds over 200 patents and patent applications. At Flagship, David has co-founded and helped build more than 20 companies across life sciences, technology and sustainability, including Seres Therapeutics (NASDAQ: MCRB), Joule Unlimited, Evelo Biosciences, Eleven Biotherapeutics (NASDAQ: EBIO), LS9 (acquired by Renewable Energy Group), Axcella Health and Indigo Agriculture. The thread uniting David’s work is an abiding enthusiasm for solving complex global challenges. David is particularly interested in the issue of sustainability because of its unprecedented intricacy—which applies broadly to our healthcare system, our environment and beyond. As a member of the Leadership Council of the United Nations Sustainable Development Solutions Network, David has actively sought to think globally about important problems.

David is the recipient of several awards and honors for his work. He was elected as a 2014 Young Global Leader by the World Economic Forum. Additional accolades include recognition in 2013 in the PharmaVOICE 100 as one of the 100 most inspiring people in the life-sciences industry; inclusion on the Boston Business Journal’s 40 under 40 list in 2012; and being named as one of 12 Innovators Reshaping Reality by the U.S. State Department in 2008, alongside pioneers such as Craig Venter and Tim Berners-Lee. In 2007, David was named by the Technology Review as Innovator of the Year on the publication’s annual TR35 list. David’s companies and their innovations have been awarded with over 150 additional awards and honors. Outside of his traditional business interests, David actively supports education and music, with a common theme of applying entrepreneurial principles to each. He serves on the board of the Hackley School and the board of the Juventas New Music Ensemble. David was formerly on the board of trustees at MIT and the board of the Boston Philharmonic Orchestra. David received his M.D. from the Harvard Medical School through the Harvard-MIT Health Sciences and Technology program. He completed his Ph.D. in MIT’s Biological Engineering Division and conducted his research in the labs of Dr. Robert Langer and Dr. Ram Sasisekharan.